10-Q · May 14, 2026
Jupiter Neurosciences reported a significant decline in revenues for Q4 2025, with actual revenue of $21,796, far below estimates of $107,000, and an EPS of -$0.07 compared to expectations of -$0.06. Management…
Earnings analysis · 10-Q
JUNS earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include current-period revenue, EPS, margin, balance-sheet, segment, or cash-flow figures, so quarter-over-quarter and year-over-year operating trends cannot be quantified. The filing…
Read full summary
The supplied 10-Q text does not include current-period revenue, EPS, margin, balance-sheet, segment, or cash-flow figures, so quarter-over-quarter and year-over-year operating trends cannot be quantified. The filing nevertheless presents a materially adverse financial profile: management says cash is insufficient for the next 12 months, substantial additional capital is required, and substantial doubt exists about the company’s ability to continue as a going concern. Nasdaq compliance remains unresolved by the August 25, 2026 deadline, while disclosure controls were deemed ineffective as of June 30, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Reverse split completed
The company completed a 1-for-75 reverse stock split on August 6, 2026. The transaction reduced outstanding shares from approximately 57,756,143 to approximately 770,081, primarily to address Nasdaq’s $1.00 minimum bid-price requirement.
-
Strategic asset license executed
Jupiter Neurosciences entered into a Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. dated July 20, 2026, adding a strategic asset transaction during the quarter.
-
No material legal proceedings
As of June 30, 2026, the company stated that it was not party to any material legal or arbitration proceedings and that no governmental proceedings were pending or, to its knowledge, contemplated.
What to watch
-
Insufficient liquidity and going concern
Management stated that the current cash balance is insufficient to fund planned operations and satisfy obligations for the next 12 months, requiring substantial additional capital. Failure to raise financing could force the company to reduce or cease operations, pursue a wind-down, or seek bankruptcy or insolvency protection.
-
Nasdaq compliance deadline
Nasdaq granted the company until August 25, 2026 to regain compliance with both the $1.00 minimum bid-price requirement and the $35 million minimum market value of listed securities requirement. The 1-for-75 reverse split addresses only the bid-price deficiency and does not directly address the market-value requirement.
-
Material internal-control weaknesses
As of June 30, 2026, management concluded that disclosure controls and procedures were ineffective due to a material weakness in segregating financial transaction processing and reporting. The company also stated that it does not have a formal internal control environment operating effectively and may identify additional material weaknesses.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; outlook may be addressed separately in an earnings release or call.
Earlier filings 4
10-K · April 1, 2026
Jupiter Neurosciences remains a clinical-stage company centered on JOTROL™, an enhanced resveratrol platform, while launching a consumer supplement line (Nugevia) with initial DTC shipments beginning in Q4 2025.…
10-Q · November 14, 2025
Jupiter Neurosciences reported a sharply wider operating loss in Q3 2025 as SG&A and R&D surged, producing a quarterly net loss of $2,288,034 (EPS $(0.07)) versus a loss of $591,021 (EPS $(0.02)) in the year-ago…
10-Q · August 19, 2025
Jupiter Neurosciences reported no product revenue and a Q2 net loss of $2,252,965 (EPS $(0.07)) compared with net income of $313,123 (EPS $0.01) in Q2 2024, driven by sharply higher R&D and G&A. Cash fell to $1,878,247…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.